Evidence map›Paper›PMID 41733386›Full record

ArticleJournal of clinical microbiology2026

Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline.

Helio S Sader, Rodrigo E Mendes, David P Nicolau, Kristie K Zappas, Mariana Castanheira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Helio S SaderElement Iowa City (JMI Laboratories), North Liberty, Iowa, USA.ORCID 0000-0001-7022-6644
Rodrigo E MendesElement Iowa City (JMI Laboratories), North Liberty, Iowa, USA.ORCID 0000-0002-8648-1137
David P NicolauInnoviva Specialty Pharmaceuticals, Waltham, Massachusetts, USA.
Kristie K ZappasInnoviva Specialty Pharmaceuticals, Waltham, Massachusetts, USA.
Mariana CastanheiraElement Iowa City (JMI Laboratories), North Liberty, Iowa, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftobiprole is an advanced-generation cephalosporin active against methicillin-resistant IMPORTANCE: Ceftobiprole was recently (April 2024) approved for clinical use in the United States but susceptibility testing is still not available on commercial automated susceptibility testing systems and may not be available for some time. In the interim, one possible strategy to assess ceftobiprole susceptibility would be to apply the susceptibility results of ceftaroline as a surrogate marker of susceptibility. This strategy could facilitate rapid clinical use of ceftobiprole in the United States pending the more necessary availability of commercial susceptibility testing devices to direct testing ceftobiprole.

Indexed as

Anti-Bacterial AgentsBacteriaCephalosporinsCeftarolineHumansMicrobial Sensitivity TestsThird Generation CephalosporinsUnited StatesAnti-Bacterial AgentsCeftarolineceftobiproleCephalosporinsThird Generation CephalosporinsceftarolineceftobiproleEscherichia coliHaemophilus influenzaeKlebsiella pneumoniaeStaphylococcus aureusStreptococcus pneumoniae

Identifiers

PMID41733386
PMCPMC13059735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.